Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 19/20 | 0.51 |
| ▸ | TDO2 | P48775 | 7/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.48 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.47 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21289910 | 0.91 | IDO1 (0.48) | IDO1TDO2CYP2C9CYP2C8SLC22A12 | |
| SCHEMBL21289920 | 0.90 | IDO1 (0.48) | IDO1TDO2CYP2C9CYP2C8SLC22A12 | |
| SCHEMBL22263460 | 0.87 | IDO1 (0.52) | IDO1TDO2CYP2C9CYP2C8CHRNA1 | |
| SCHEMBL21289936 | 0.86 | IDO1 (0.51) | IDO1TDO2CYP2C9CYP2C8CHRNA1 | |
| SCHEMBL17730175 | 0.86 | IDO1 (0.59) | IDO1TDO2CYP2C9CYP2C8CHRNA1 | |
| SCHEMBL21289269 | 0.85 | IDO1 (0.55) | IDO1TDO2CYP2C9CYP2C8CYP3A4 | |
| SCHEMBL31241523 | 0.85 | IDO1 (0.55) | IDO1TDO2CYP2C9CYP2C8CYP3A4 | |
| SCHEMBL20935434 | 0.84 | IDO1 (0.51) | IDO1TDO2CYP2C9CYP2C8CHRNA1 | |
| SCHEMBL20916335 | 0.84 | IDO1 (0.51) | IDO1TDO2CYP2C9CYP2C8CHRNA1 | |
| SCHEMBL22274771 | 0.84 | IDO1 (0.51) | IDO1TDO2CYP2C9CYP2C8CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3753926-B1 | SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR | SHANGHAI INST ORGANIC CHEMISTRY CAS (CN) | 2024-10-09 | — | — | EP | disclosed |
| US-11180497-B2 | Cyclic compounds as immunomodulating agents | ANGEX PHARMACEUTICAL, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210047290-A1 | SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2021-02-18 | — | — | US | disclosed |
| US-20210047290-A1 | SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2021-02-18 | — | — | US | disclosed |
| EP-3753926-A1 | SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2020-12-23 | — | — | EP | disclosed |
| EP-3753926-A1 | SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2020-12-23 | — | — | EP | disclosed |
| EP-3704095-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-09-09 | — | — | EP | disclosed |
| US-20200239464-A1 | CYCLIC COMPOUNDS AS IMMUNOMODULATING AGENTS | ANGEX PHARMACEUTICAL, INC. | 2020-07-30 | — | — | US | disclosed |
| US-20200239420-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-30 | — | — | US | disclosed |
| US-20200239420-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-30 | — | — | US | disclosed |
| WO-2019158051-A1 | SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR | 中国科学院上海有机化学研究所 | 2019-08-22 | — | — | WO | disclosed |
| WO-2019078968-A2 | CYCLIC COMPOUNDS AS IMMUNOMODULATING AGENTS | ANGEX PHARMACEUTICAL, INC. (US) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047290-A1 | SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR | IDO1, IDO2, TPH1 | IDO1 1/4885TDO2 5/4885CYP2C9 258/4885 |
| US-20200239420-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TPH1 | IDO1 1/4885TDO2 7/4885CYP2C9 760/4885 |
| US-20200239464-A1 | CYCLIC COMPOUNDS AS IMMUNOMODULATING AGENTS | IDO1, IDO2, INMT | IDO1 1/4885TDO2 109/4885CYP2C9 2874/4885 |
| US-11180497-B2 | Cyclic compounds as immunomodulating agents | IDO1, IDO2, INMT | IDO1 1/4885TDO2 65/4885CYP2C9 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.